The Report
“Tradjenta (Type 2 Diabetes) – Forecast and Market Analysis to 2022″ is
now available at MarketOptimizer.org. Contact sales@marketoptimizer.org with Report name in subject line and
your contact details to purchase this report or get your questions answered.
Researcher has
released its new report, “Tradjenta (Type 2 Diabetes) Forecast and Market
Analysis to 2022″. The type 2 diabetes market is mature and crowded with
inexpensive generics. Despite being marked by a late-stage pipeline filled with
me-too drugs, this market will undergo substantial growth between 2012 and
2022, more than doubling over this period. The main drivers of growth will be
the dramatic increase in disease prevalence and physicians’ efforts to delay
disease progression and reduce the costly burden of diabetic complications
through the use of combination therapies and novel branded drugs.
Tradjenta
(linagliptin) was developed by Boehringer Ingelheim and approved by the FDA in
2011. It is being marketed by Boehringer Ingelheim and Eli Lilly.
Scope
- Overview of type 2 diabetes,
including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tradjenta
including product description, safety and efficacy profiles as well as a
SWOT analysis.
- Sales forecast for Tradjenta for
the top ten countries from 2012 to 2022.
- Sales information covered for the
US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.
Complete Report is available @ http://www.marketoptimizer.org/tradjenta-type-2-diabetes-forecast-and-market-analysis-to-2022.html .
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by
understanding the changing competitive landscape for type 2 diabetes
- Effectively plan your M&A and
partnership strategies by identifying drugs with the most promising sales
potential
- Make more informed business
decisions from insightful and in-depth analysis of Tradjenta performance
- Obtain sales forecast for
Tradjenta from 2012-2022 in top ten countries (the US, France, Germany,
Italy, Spain, the UK, Japan, Brazil, India and China)
Buy the
copy of this Report @ http://www.marketoptimizer.org/contacts/purchase?rname=3438 .
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 13
3.1.3 Prognosis 14
3.1.4 Quality of Life 15
3.2 Symptoms 15
4 Disease Management 17
4.1 Treatment Overview 17
4.1.1 Diagnosis and Referrals 17
4.1.2 Treatment Guidelines 18
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25
6 Tradjenta (linagliptin) 27
6.1 Overview 27
6.2 Efficacy 28
6.3 Safety 29
6.4 SWOT Analysis 30
6.5 Forecast 31
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 37
7.3 Methodology 38
7.4 Forecasting Methodology 38
7.4.1 Diagnosed Type 2 Patients 38
7.4.2 Percent Drug-Treated Patients 39
7.4.3 Drugs Included in Each Therapeutic Class 39
7.4.4 Launch and Patent Expiry Dates 40
7.4.5 General Pricing Assumptions 40
7.4.6 Individual Drug Assumptions 41
7.4.7 Generic Erosion 41
7.5 Physicians and Specialists Included in this Study 42
7.6 About the Authors 44
7.6.1 Analyst II – CVMD 44
7.6.2 Therapy Director – CVMD and Infectious Disease 44
7.6.3 Global Head of Healthcare 45
7.7 About Researcher 46
7.8 Disclaimer 46
Inquiry
before buying this Report @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=3438 . (Single
User License : US$ 3495 And Corporate User License : US$ 10485)
For
further information on “Tradjenta (Type 2 Diabetes) – Forecast and Market
Analysis to 2022” report Contact sales@marketoptimizer.org / Call +1 888 391 5441.
